Posted on 10/11/17
Better Buy: Biogen Inc. vs. Celgene
Owning either of these large-cap biotech stocks has been a great way to get rich over the past decade. Shares of Celgene Corporation (NASDAQ:CELG) have quadrupled . . .
Posted on 10/11/17
Biogen: Upside At A Good Value
Biogen Inc.'s (BIIB) current pipeline of Alzheimer's therapies is currently extremely promising. On October 5 the stock shot up as a result of Morgan Stanley releasing . . .
Posted on 10/11/17
KalVista Pharmaceuticals Announces Collaboration with Merck
CAMBRIDGE, Mass.--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that . . .
Posted on 10/11/17
Kaleido Biosciences and CoreBiome Partner
BEDFORD, Mass.--(BUSINESS WIRE)--Kaleido Biosciences, a clinical-stage biotechnology company developing novel chemistries to unlock the power of the human microbiome, today announced an agreement with CoreBiome, a . . .
Posted on 10/9/17
Spero Therapeutics Files for IPO
CAMBRIDGE, Mass., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug . . .
Posted on 10/6/17
Amgen And LabCentral Open Nomination Process For Lab Residency
Amgen (NASDAQ: AMGN) and LabCentral today announced that the nomination process to submit proposals to receive an Amgen-sponsored LabCentral Golden Ticket is open for interested life . . .
Posted on 10/6/17
Mauna Kea Technologies Renews Its Equity Financing Facility
PARIS & BOSTON--(BUSINESS WIRE)--Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announces the implementation of . . .
Posted on 10/6/17
BMC HealthNet Plan Awarded MassHealth MCO Program Contract
Boston Medical Center (BMC) HealthNet Plan has been selected by MassHealth to manage primary, behavioral, pharmacy and specialty care for members of the MassHealth Managed Care . . .
Posted on 10/6/17
Here's Why Alnylam Pharmaceuticals Rallied 32.7% in September
What happenedPowered by encouraging phase 3 results for an important pipeline drug, shares of clinical-stage biotech Alnlyam Pharmaceuticals (NASDAQ:ALNY), which focuses on RNAi treatments, gained 33% . . .
Posted on 10/5/17
Hologic Enters into Amended and Restated Five-Year Secured Credit Agreement
Hologic, Inc. (NASDAQ: HOLX) announced today that the Company has entered into an amended and restated credit agreement consisting of a new, five-year $1.5 billion senior . . .
Posted on 10/5/17
ImmunoGen Proposes Public Offering of Common Stock
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (NASDAQ: IMGN) today announced that it intends to offer and sell, subject to market and other conditions, 13,000,000 shares of its common . . .
Posted on 10/4/17
Will Berkshire Hathaway Acquire General Mills?
It has been a while since Berkshire Hathaway (NYSE:BRK.A) (BRK.B) made a major acquisition. As a result, its cash pile has steadily grown and has thus . . .
Posted on 10/4/17
Why bluebird bio, Inc. Stock Gained 10% in September
What happenedShares of bluebird bio, Inc. (NASDAQ:BLUE), a clinical-stage biotech developing cell-based therapies, rose 10% in September according to data from S&P Global Market Intelligence. Although . . .
Posted on 10/4/17
Nimbus Therapeutics and Celgene Enter Long-Term Strategic Immunology Alliance
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a biotechnology company applying deep computational expertise throughout drug discovery and development, announced today the initiation of a long-term strategic alliance with . . .
Posted on 10/4/17
Goldfinch Bio and NEPTUNE Announce Collaboration
Goldfinch Bio, a company singularly focused on discovering and developing precision therapies to treat patients with kidney disease, today announced a collaboration with NEPTUNE, a leading . . .
Posted on 10/3/17
Deciphera Pharmaceuticals Closes IPO
WALTHAM, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced . . .
Posted on 10/3/17
Sarepta Therapeutics Stock Soars Despite Adverse Event Worries
Late last week, some Sarepta Therapeutics (NASDAQ:SRPT) investors were worried. Now the weekend is over, and all of those worries seem to have dissipated.Concerns arose after . . .
Posted on 10/2/17
Copyright Clearance Center’s Subsidiary RightsDirect Partners with Meteo
RightsDirect, a subsidiary of Copyright Clearance Center, Inc. (CCC), today announced they are partnering with Meteo Inc., a leading provider of Japanese medical information. Using RightFind® . . .
Posted on 10/2/17
A Major Bank Rates Buffett's Berkshire Hathaway a Buy. Should You Pull the Trigger?
Analysts at investment banks cover a great many stocks, but some big names aren't as widely tracked as you might expect. Such is the case with . . .
Posted on 9/29/17
Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio
This version of our ongoing better buy series pits two development-stage biotechs, Bellicum Pharmaceuticals (NASDAQ:BLCM) and bluebird bio (NASDAQ:BLUE), against each other. The companies have something . . .
Posted on 9/29/17
A Major Bank Rates Buffett's Berkshire Hathaway a Buy. Should You Pull the Trigger?
Analysts at investment banks cover a great many stocks, but some big names aren't as widely tracked as you might expect. Such is the case with . . .
Posted on 9/28/17
Deciphera Pharmaceuticals Prices IPO
WALTHAM, Mass., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today . . .
Posted on 9/28/17
Intarcia Provides Corporate Update
Intarcia Therapeutics, Inc., a privately held biopharmaceutical company committed to developing innovative therapies to enhance treatment and prevention outcomes in serious chronic diseases, today announced that . . .
Posted on 9/28/17
Casebia Therapeutics Announces License and Collaboration Agreements with Seattle Children’s Research Institute
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Casebia Therapeutics, a leading genetic engineering company, and Seattle Children’s Research Institute today announced an exclusive license agreement and research collaboration to explore new . . .
Posted on 9/28/17
Nightstar Prices IPO
LEXINGTON, Mass. & LONDON--(BUSINESS WIRE)--Nightstar Therapeutics plc, a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced the pricing of its initial . . .
Boston
